Abstract: The present invention provides a method of determining whether a patient with inflammatory bowel disease (IBD) and who has been treated with anti TNF? therapy is in immunological remission (IR), said method comprising determining the level of a cytokine selected from TNF?, IL-17 and IFN-y in a Gl mucosal sample from said patient. Also provided are methods of prognosis and treatment using said method of determination, in particular discontinuing treatment if said patient is in IR and continuing treatment if said patient is not in IR.
Type:
Grant
Filed:
December 23, 2013
Date of Patent:
July 3, 2018
Assignee:
UNIVERSITY OF TROMSØ
Inventors:
Jon Florholmen, Trine Olsen, Renathe Rismo, Rasmus Goll, Guanglin Cui
Abstract: The present invention provides a method for diagnosing, identifying or monitoring proliferative disorders due to e.g cancer preferably breast cancer in a subject by measuring the change of gene expression in a sample e.g. a blood sample. The present invention also encompasses oligonucleotide probes and primers corresponding to genes differentially expressed compared to the expression pattern in a normal cell. The use of such oligonucleotides is also an aspect of the invention together with a kit comprising said oligonucleotides.
Abstract: The present invention relates to compounds of Formula (I) wherein R1 and R3 are hydrogen; R2 and R4, which may be the same or different, are hydrogen, a C1-6 alkyl group optionally substituted by an aryl group which may itself be substituted, the substituent group including an alkyl group or an —OR group in which R is a C1-3 alkyl group, with one or more hydrogen atoms optionally replaced with a halogen atom; or an aryl group which may be substituted, the substituent group including an alkyl group or an —OR group in which R is a C1-3 alkyl group, with one or more hydrogen atoms optionally replaced with a halogen atom; with the proviso that R2 and R4 are not both hydrogen; the atom of R4 which is attached to C? is either a saturated carbon atom or an atom which is part of a 1 substituted aromatic ring; (AA)0-5 is an amino acid, amino acid derivative, peptide of up to 5 amino acids or a peptidomimetic thereof which optionally incorporates an N-terminal capping group, when the group is (AA)0 an N-terminal cappin
Type:
Application
Filed:
January 8, 2013
Publication date:
January 15, 2015
Applicant:
University of Tromsø
Inventors:
Tore Lejon, John Sigurd Svendsen, Alexey Gorovoy, Olga Gozhina
Abstract: The present invention is directed to intrauterine devices that release progestins or an inflammatory cytokine after placement. These devices can be used to reduce the risk of a woman developing endometrial cancer. The invention is also directed to therapeutic methods in which a sample of uterine cells obtained from a woman is assayed to determine the extent to which PTEN null clones (latent endometrial precancers) are present. In cases where the number of such null clones is high, the woman is administered an intrauterine device that releases either a progestin or an inflammatory cytokine.
Type:
Grant
Filed:
January 22, 2007
Date of Patent:
December 28, 2010
Assignees:
The Brigham and Women's Hospital, Inc., University of Tromsø
Inventors:
George Mutter, Akila Viswanathan, Anne Ørbo